Ramantamig Biosimilar Trispecific Antibody (CD3 × GPRC5D × BCMA) for Research

Cat No.: GMP-Bios-INN-1356

Anti-CD3E therapeutic antibody (Pre-made Ramantamig biosimilar,Trispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ramantamig (development codes JNJ-79635322/JNJ-5322) is a trispecific antibody targeting CD3 and GPRC5D. It is developed by Janssen Research & Development, LLC for Multiple Myeloma in Phase III development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1356-1mg 1mg
GMP-Bios-INN-1356-10mg 10mg
GMP-Bios-INN-1356-100mg 100mg
GMP-Bios-INN-1356-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Ramantamig biosimilar, Trispecific Mixed mAb and scFv, Anti-CD3E;GPRC5D;TNFRSF17/CD269/BCMA/TNFRSF13A Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody
INN Name Ramantamig
Target CD3E;GPRC5D;TNFRSF17/CD269/BCMA/TNFRSF13A
Format Trispecific Mixed mAb and scFv; Bispecific entry
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G1;na
VD LC Lambda;Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status TBC
100% SI Structure None;None
99% SI Structure None;None
95-98% SI Structure None;None
Year Proposed 2025
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC